MarginsXMarginsX
Home › Markets › Health Care › ALMS

Alumis Inc. (ALMS)

ALMS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$5.14
-8.21% on the day
Market cap
$667.3M
Small cap
Revenue · 2025
$24.1M
No prior year to compare
Net income · 2025
-$243.3M
-1011.7% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1847367/000184736726000006/0001847367-26-000006-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerALMS on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2024
SEC CIK0001847367
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$24.1M
Net income-$243.3M
Operating income-$453.8M
Net margin-1011.7%
Operating margin-1886.9%
Revenue growthNo prior-year revenue to compare
Cash$89.7M
Total assets$411.9M
P/E (computed)Net income was not positive
P/S (computed)27.7×

Warning signs

Cash runway
2.2 months
$57.7M cash at September 30, 2026
Share count, 1 year
No year-earlier count
Going-concern doubt
Yes
10-Q filed November 12, 2026
Insider net buying, 12 months
$36.4M
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"The Company believes that, based on its current operating plan, its existing cash, cash equivalents and marketable securities of $ 431.3 million as of September 30, 2026, will not be sufficient to meet its operating and capital requirements for at least 12 months from the date of issuance of these unaudited condensed consolidated financial statements and there is substantial doubt about the Company's ability to conti"
10-Q 2026-11-12
Cash and burn$57.7M cash; operating cash flow -$80.0M a quarter.Report 2026-09-30
Shares outstanding129,820,970 (2026-11-05).Cover page 2026-11-05
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-01-08
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers LLP, San Jose, California, United StatesPCAOB Form AP 2026-03-27
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $38.0M, sold $1.5M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$1.9M-$94.9M-$79.6M$57.7MNo debt tags$7.2M10-Q 2026-11-12
Q2 2026
2026-06-30
$1.7M-$142.2M-$81.5M$63.7MNo debt tags$7.4M10-Q 2026-08-13
Q1 2026
2026-03-31
$1.7M-$93.1M-$87.1M$63.9MNo debt tags$8.4M10-Q 2026-05-14
Q4 2025
2025-12-31
$1.9M-$92.9M-$71.9M$89.7MNo debt tags$24.1M10-K 2026-03-19
Q3 2025
2025-09-30
$2.1M-$110.8M-$110.9M$65.3MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q2 2025
2025-06-30
$2.7M$59.3M-$106.4M$151.8MNo debt tagsNeeds four quarters10-Q 2026-08-13
Q1 2025
2025-03-31
$17.4M-$99.0M-$80.4M$128.5MNo debt tagsNeeds four quarters10-Q 2026-05-14
Q4 2024
2024-12-31
Not filed-$94.8M-$74.8M$169.5MNo debt tagsNeeds four quarters10-K 2026-03-19

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-3ASR2026-03-19
Latest annual report10-K2026-03-19
Latest quarterly / interim10-Q2026-11-12
Latest current report8-K2026-11-12
Latest proxyDEFA14A2026-05-18

Source: SEC EDGAR submissions feed, 250 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-7.1%
1 month-14.6%
3 months-77.1%
Year to date-42.6%
1 year+6.1%
From 52-week high-81.5%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
JANXJanux Therapeutics Inc.$10.92-3.96%$668.1M
NVCTNuvectis Pharma Inc.$19.11-5.58%$657.2M
APMDApnimed Inc.$16.28-3.78%$677.7M
ANNXAnnexon Inc.$3.57-8.93%$681.0M
KURAKura Oncology Inc.$7.09-8.75%$651.4M
BCAXBicara Therapeutics Inc.$9.75-2.69%$647.3M
ANLAdlai Nortye Group Ltd.$10.03-5.47%$645.9M
OLMAOlema Oncology Inc.$7.36-2.65%$644.8M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier